Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – vedolizumab

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Vedolizumab Testmiljö

Vedolizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.

  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.

  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.

  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.

  5. EMA. Entyvio. CHMP Assessment Report 2014-03-27. http://goo.gl/n15FkS

  6. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129-138.

  7. P Wils, P Seksik, C Stefanescu, S Nancey, M Allez, D Laharie, G Pineton De Chambrun, R Altwegg, C Gilletta, L Vuitton, S Viennot, M Serrero, M Fumery, G Savoye, M Collins, F Goutorbe, H Brixi, G Bouguen, N Tavernier, M Boualit, A Amiot, V Abitbol, B Pariente. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy. Poster P 447. Abstracts of the 15th Congress of ECCO – European Crohn’s and Colitis Organisation. 2020.

  8. Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021.

  9. Chambers CD PhD, Adams J, Xu R, Johnson Diana, Luo Y J. The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update. Am J Gastroenterol. 2021;116:S367-S368.

  10. Flanagan E, Gibson PR, Wright EK et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(0):1551-1662.

  11. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.
  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.
  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.
  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.
  5. EMA. Entyvio. CHMP Assessment Report 2014-03-27. http://goo.gl/n15FkS
  6. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129-138.
  7. P Wils, P Seksik, C Stefanescu, S Nancey, M Allez, D Laharie, G Pineton De Chambrun, R Altwegg, C Gilletta, L Vuitton, S Viennot, M Serrero, M Fumery, G Savoye, M Collins, F Goutorbe, H Brixi, G Bouguen, N Tavernier, M Boualit, A Amiot, V Abitbol, B Pariente. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy. Poster P 447. Abstracts of the 15th Congress of ECCO – European Crohn’s and Colitis Organisation. 2020.
  8. Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021.
  9. Chambers CD PhD, Adams J, Xu R, Johnson Diana, Luo Y J. The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update. Am J Gastroenterol. 2021;116:S367-S368.
  10. Flanagan E, Gibson PR, Wright EK et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(0):1551-1662.
  11. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.